Form D · Biotechnology
Brainsway Ltd.
Jerusalem, L3 · CIK 0001505065
Offering snapshot reported Oct 15, 2024 · SEC filing
- Reported sold
- $20M Offering amount: $20M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 15, 2024 | Initial | $20,000,009 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-526676
This Form D is being filed in connection with the issuance of 2,103,745 ADSs, each representing two ordinary shares of the Company, at a purchase price of $9.50686 per ADS and a warrant to purchase 1,500,000 ADSs at an exercise price of $9.50686 per ADS.
Source: Form D, filed Oct 15, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yossi Ben Shalom | Director |
| Ami Boehm | Director |
| Avner Hagai | Director |
| Hadar Levy | Executive |
| Avner Lushi | Director |
| Ido Marom | Executive |
| Eti Mitrany | Director |
| Karen Sarid | Director |
| David Zacut | Director |
| Abraham Zangen | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
16 Hartum Street Rad Tower, 14 Th Floor, Har Hahotzvim
Jerusalem, L3, 9777516
Jerusalem, L3, 9777516